Compare LSPD & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSPD | ENOV |
|---|---|---|
| Founded | 2005 | 1995 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Fluid Controls |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2020 | 2008 |
| Metric | LSPD | ENOV |
|---|---|---|
| Price | $11.36 | $29.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 6 |
| Target Price | $13.63 | ★ $51.17 |
| AVG Volume (30 Days) | 670.3K | ★ 853.5K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,157,458,000.00 | ★ $2,233,266,000.00 |
| Revenue This Year | $14.32 | $9.27 |
| Revenue Next Year | $11.78 | $4.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.24 | 11.57 |
| 52 Week Low | $7.34 | $25.47 |
| 52 Week High | $17.89 | $49.75 |
| Indicator | LSPD | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 47.27 |
| Support Level | $10.98 | $26.69 |
| Resistance Level | $11.45 | $30.93 |
| Average True Range (ATR) | 0.39 | 1.26 |
| MACD | -0.04 | 0.11 |
| Stochastic Oscillator | 28.50 | 54.40 |
Lightspeed Commerce Inc provides an omni-channel commerce-enabling SaaS platform. Its software platform provides customers with the functionality it needs to engage with consumers, manage their operations, accept payments, and grow their businesses. The company sells its platform through a direct sales force in the United States, Canada, United Kingdom, Australia, and other countries. It derives a majority of its revenue from the United States.
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.